Comparative Pharmacology
Head-to-head clinical analysis: ENOXAPARIN SODIUM versus LOVENOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOXAPARIN SODIUM versus LOVENOX.
ENOXAPARIN SODIUM vs LOVENOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enoxaparin binds to antithrombin III (ATIII) via its pentasaccharide sequence, enhancing ATIII-mediated inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). It preferentially inhibits factor Xa over thrombin (anti-Xa:anti-IIa ratio ~3.6:1).
Low molecular weight heparin (LMWH) that binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin, thereby preventing thrombus formation.
1 mg/kg subcutaneous every 12 hours or 1.5 mg/kg subcutaneous once daily
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis in abdominal surgery, hip or knee replacement; 30 mg subcutaneously every 12 hours for prophylaxis in medical patients; 0.5 mg/kg subcutaneously once daily for prophylaxis in patients with acute coronary syndrome.
None Documented
None Documented
4.5-7 hours after single subcutaneous dose; prolonged to 8-12 hours in renal impairment (CrCl <30 mL/min). Clinical context: maintains anti-Xa activity for 12 hours with once-daily dosing.
Terminal half-life: 4.5-7 hours after subcutaneous administration; prolonged in renal impairment (up to 16 hours with CrCl <30 mL/min), requiring dose adjustment.
Renal (40-60% as unchanged drug via glomerular filtration and saturable tubular reabsorption). Biliary/fecal: negligible (<10%).
Renal: 40-60% as active and inactive fragments via glomerular filtration and tubular secretion; biliary/fecal: minimal, <10%.
Category A/B
Category C
Low Molecular Weight Heparin
Low Molecular Weight Heparin